About xBiologix, Inc.

Making Proteins Work®

The war on cancer is at a crossroad, a point at which visualizing disease progression and treatment in whole tissue, in and around tumors, is critically important to understanding and ultimately curing cancer. Available technologies, such as genetic sequencing, cytometry and even multiplexed immunofluorescent imaging, either do not provide the spatial context or are too complex and expensive for use in pathology or clinical settings, paradoxically failing to meet this moment owing to the complexity, skills and expense incurred by these technologies. By contrast, immunohistochemistries (IHCs) are simple and cheap— a perfect fit for research, pathology and clinical settings— but IHCs only image one biomarker at a time, a poor match with spatial biology.

xBiologix's "one pot" massively multiplexed immunofluorescent IHCs (mIHC/IF) brings simple fluorescent microscopy platforms and IHCs protocol together, making profiling the required number of biomarkers available to virtually any research scientist, pathologist or clinician, and heralding the dawn of a new age in spatial biology.

Our passion for simplifying health science workflows comes to this crossroad in the war on cancer armed with mIHC/IFs so scientists can focus on making discoveries, so drug trials can screen for the best candidates, and so clinicians can personalize diagnosis and monitor an individual patient's treatment, fulfilling personalized medicine's promise.

Making Proteins Work®

xBiologix Technology

Making Proteins Work®

xBiologix's technology platform brings the 2022 Nobel Prize in Chemistry— for the invention of bioorthogonal click chemistry— together with nature's basic building machinery— DNA, transcription and translation— to create best in class products supporting health science research, drug discovery and diagnostics.

Quantitative conjugation— specific, oriented, bioorthogonal and highly efficient conjugate labeling techniques for proteins, especially antibodies— is the hallmark of our platform. Quantitative conjugation uses genetic engineering and click chemistry driven reaction kinetics to resolve the key protein labeling problem by ensuring that each carrier protein has one and only one payload/label, and that the payload is integrated into the target protein's structure without interfering with the protein's native kinetics or folding.

Quantitative conjugation means our customers get ready-to-use antibody-oligo conjugates that elevate conventional fluorescent microscopy instruments from Nikon®, Keyence®, Leica®, etc., to levels of performance that exceed existing spatial platforms— using highly multiplexed, cyclic immunofluorescence strategies for spatial biology.

Quantitative conjugation means off-the-shelf convenience targeting many sought-after customizations that work on existing spatial platforms, providing speed, confidence & flexibility.

xBiologix Products

Making Proteins Work®

xBiologix provides products and service supporting customers in—

Spatial biology with ready-to-use antibody-oligo conjugates and complementary imaging oligos with cleavable fluorophores. Our antibodiy oligo and complementary fluorophores are sold individually or as tissue/pathway specific, pre-validated panels. Our "one pot" massively multiplexed immunofluorescent IHCs (mIHC/IF) protocol mimics IHC protocol with one antibody binding step, radically simplifing the piblished cyclic immunofluorescence protocols— a.k.a cycIF.

Point-of-Care diagnostics for blood borne disease and hematologic disorders that empower the frontlines of healthcare with inexpensive, portable and easy-to-use diagnostic devices.

At-Home infectious disease diagnostics that rival the sensitivity of lab based molecular tests.

To find out more about or to order our products, contact us at sales@xbiologix.com.

xBiologix, Inc.

Want to know more about how our technology or services can help accelerate your research, discovery or personalize your diagnostic?

Contact us. We're Making Proteins Work®.